Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables.

[1]  R. Groszmann,et al.  Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis , 2011, Hepatology.

[2]  Chun-Jen Liu,et al.  Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. , 2011, Carcinogenesis.

[3]  Mahmoud A. Khattab,et al.  1161 ASSOCIATION OF SERUM ADIPOCYTOKINES WITH LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4 , 2011 .

[4]  M. Ziol,et al.  Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. , 2010, Journal of hepatology.

[5]  J. Dufour,et al.  Significance of serum adiponectin levels in patients with chronic liver disease , 2010, Clinical science.

[6]  M. Walker,et al.  Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals , 2009, Diabetologia.

[7]  G. Marchesini,et al.  Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis , 2009, Hepatology.

[8]  A. Sonmez,et al.  The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. , 2008, Diabetes research and clinical practice.

[9]  R. Franchis.  Non-invasive (and minimally invasive) diagnosis of oesophageal varices. , 2008 .

[10]  A. Sanyal,et al.  Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis , 2007, The American Journal of Gastroenterology.

[11]  R. Groszmann,et al.  Vascular endothelial dysfunction in cirrhosis. , 2007, Journal of hepatology.

[12]  J. Flier,et al.  The adipocyte as an active participant in energy balance and metabolism. , 2007, Gastroenterology.

[13]  D. Rockey.  Hepatic fibrosis, stellate cells, and portal hypertension. , 2006, Clinics in liver disease.

[14]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[15]  Ramon Planas,et al.  Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. , 2005, The New England journal of medicine.

[16]  H. Tilg,et al.  Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis , 2005, Journal of internal medicine.

[17]  R. Franchis,et al.  Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. , 2005, Journal of hepatology.

[18]  F. Anania,et al.  The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. , 2005, The American journal of pathology.

[19]  M. Mori,et al.  Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[20]  R. de Franchis.  Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. , 2005, Journal of hepatology.

[21]  P. Schiedermaier.  Splanchnic hemodynamics: cirrhotic versus non‐cirrhotic portal hypertension , 2004 .

[22]  M. Manns,et al.  Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. , 2004, American journal of physiology. Endocrinology and metabolism.

[23]  J. Kench,et al.  Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index , 2004, Hepatology.

[24]  A. Zaman,et al.  Changing Compliance to the American College of Gastroenterology Guidelines for the Management of Variceal Hemorrhage: A Regional Survey , 2004, American Journal of Gastroenterology.

[25]  T. Poynard,et al.  Fibrogenic impact of high serum glucose in chronic hepatitis C. , 2003, Journal of hepatology.

[26]  R. Franchis,et al.  Natural history of portal hypertension in patients with cirrhosis. , 2001, Clinics in liver disease.

[27]  R. Groszmann,et al.  Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. , 1992, Journal of hepatology.